Cart
sales@molnova.com
ICA-105574
CAS No. 316146-57-3
ICA-105574( ICA | 3-nitro-N-[4-phenoxyphenyl]-benzamide )
Catalog No. M24250 CAS No. 316146-57-3
ICA-105574 is an activator of hERG that binds to the channel to remove inactivation, thus increasing peak current amplitude and shortening the action potential. It also modulates activation kinetics of the channel.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 88 | In Stock |
|
| 5MG | 80 | In Stock |
|
| 10MG | 140 | In Stock |
|
| 25MG | 297 | In Stock |
|
| 50MG | 458 | In Stock |
|
| 100MG | 672 | In Stock |
|
| 200MG | 918 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameICA-105574
-
NoteResearch use only, not for human use.
-
Brief DescriptionICA-105574 is an activator of hERG that binds to the channel to remove inactivation, thus increasing peak current amplitude and shortening the action potential. It also modulates activation kinetics of the channel.
-
DescriptionICA-105574 is an activator of hERG that binds to the channel to remove inactivation, thus increasing peak current amplitude and shortening the action potential. It also modulates activation kinetics of the channel.
-
In Vitro——
-
In Vivo——
-
SynonymsICA | 3-nitro-N-[4-phenoxyphenyl]-benzamide
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorhERG
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number316146-57-3
-
Formula Weight334.33
-
Molecular FormulaC19H14N2O4
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESC1=CC=C(C=C1)OC2=CC=C(C=C2)NC(=O)C3=CC(=CC=C3)[N+](=O)[O-]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Meng J , Shi C , Li L , et al. Compound ICA-105574 prevents arrhythmias induced by cardiac delayed repolarization[J]. European Journal of Pharmacology, 2013, 718(1-3):87-97.
molnova catalog
related products
-
Glaucocalyxin A
Glaucocalyxin A-SBE-β-CD could be useful with a better solubility and sustained function in drug delivery.
-
Poziotinib hydrochlo...
Poziotinib hydrochloride irreversibly inhibits EGFR (HER1 or ErbB1), including EGFR mutants, HER2, and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors.?It is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor with potential antineoplastic activity.?
-
Dihydroberberine
Dihydroberberine has anti-atherosclerotic anti-inflammatory hypolipidemic and antitumor activities. It inhibits human ether-a-go-go-related gene (hERG) channels and remarkably reduces Hsp90 expression and its interaction with hERG.
